{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:42:02Z","timestamp":1793900522064,"version":"4.8.0"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI 110495"],"award-info":[{"award-number":["U19 AI 110495"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00018-021-03874-y","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T18:02:40Z","timestamp":1624039360000},"page":"5527-5542","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions"],"prefix":"10.1007","volume":"78","author":[{"given":"Hamid","family":"Mattoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9905-875X","authenticated-orcid":false,"given":"Shiv","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"issue":"12","key":"3874_CR1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","volume":"15","author":"JHW Distler","year":"2019","unstructured":"Distler JHW et al (2019) Shared and distinct mechanisms of fibrosis. Nat Rev Rheumatol 15(12):705\u2013730","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"3874_CR2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MCP.0000000000000191","volume":"21","author":"BA Helling","year":"2015","unstructured":"Helling BA, Yang IV (2015) Epigenetics in lung fibrosis: from pathobiology to treatment perspective. Curr Opin Pulm Med 21(5):454\u2013462","journal-title":"Curr Opin Pulm Med"},{"issue":"8","key":"3874_CR3","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","volume":"66","author":"EL Herzog","year":"2014","unstructured":"Herzog EL et al (2014) Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 66(8):1967\u20131978","journal-title":"Arthritis Rheumatol"},{"issue":"127","key":"3874_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ et al (2013) Scleroderma lung disease. Eur Respir Rev 22(127):6\u201319","journal-title":"Eur Respir Rev"},{"issue":"19","key":"3874_CR5","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli A, Avvedimento EV, Krieg T (2009) Scleroderma. N Engl J Med 360(19):1989\u20132003","journal-title":"N Engl J Med"},{"issue":"6","key":"3874_CR6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788\u2013824","journal-title":"Am J Respir Crit Care Med"},{"key":"3874_CR7","doi-asserted-by":"crossref","first-page":"17074","DOI":"10.1038\/nrdp.2017.74","volume":"3","author":"FJ Martinez","year":"2017","unstructured":"Martinez FJ et al (2017) Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 3:17074","journal-title":"Nat Rev Dis Primers"},{"issue":"153","key":"3874_CR8","doi-asserted-by":"crossref","first-page":"190021","DOI":"10.1183\/16000617.0021-2019","volume":"28","author":"V Somogyi","year":"2019","unstructured":"Somogyi V et al (2019) The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev 28(153):190021","journal-title":"Eur Respir Rev"},{"issue":"21","key":"3874_CR9","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2012","unstructured":"Idiopathic Pulmonary Fibrosis Clinical Research (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366(21):1968\u20131977","journal-title":"N Engl J Med"},{"issue":"1","key":"3874_CR10","doi-asserted-by":"crossref","first-page":"e8959","DOI":"10.1371\/journal.pone.0008959","volume":"5","author":"SR Gilani","year":"2010","unstructured":"Gilani SR et al (2010) CD28 down-regulation on circulating CD4 T cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLOS ONE 5(1):e8959","journal-title":"PLOS ONE"},{"issue":"4","key":"3874_CR11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(4):431\u2013440","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 5","key":"3874_CR12","doi-asserted-by":"crossref","first-page":"S417","DOI":"10.1513\/AnnalsATS.201605-341AW","volume":"13","author":"A Pardo","year":"2016","unstructured":"Pardo A, Selman M (2016) Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann Am Thorac Soc 13(Suppl 5):S417\u2013S421","journal-title":"Ann Am Thorac Soc"},{"key":"3874_CR13","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00018-020-03693-7","volume":"78","author":"THG Phan","year":"2020","unstructured":"Phan THG et al (2020) Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci 78:2031","journal-title":"Cell Mol Life Sci"},{"issue":"10103","key":"3874_CR14","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390(10103):1685\u20131699","journal-title":"Lancet"},{"issue":"7","key":"3874_CR15","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","volume":"75","author":"EG Wirz","year":"2016","unstructured":"Wirz EG et al (2016) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75(7):1285\u20131292","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3874_CR16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold AM et al (2019) Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort. Am J Respir Crit Care Med 200(10):1258\u20131266","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3874_CR17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-017-3936-7","volume":"37","author":"M Rubio-Rivas","year":"2018","unstructured":"Rubio-Rivas M et al (2018) First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. Clin Rheumatol 37(4):999\u20131009","journal-title":"Clin Rheumatol"},{"issue":"5","key":"3874_CR18","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler O et al (2020) Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 55(5):1902026","journal-title":"Eur Respir J"},{"issue":"3","key":"3874_CR19","doi-asserted-by":"crossref","first-page":"e0214202","DOI":"10.1371\/journal.pone.0214202","volume":"14","author":"PD Burbelo","year":"2019","unstructured":"Burbelo PD et al (2019) Autoantibodies are present before the clinical diagnosis of systemic sclerosis. PLOS ONE 14(3):e0214202","journal-title":"PLOS ONE"},{"issue":"3","key":"3874_CR20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","volume":"70","author":"J Avouac","year":"2011","unstructured":"Avouac J et al (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70(3):476\u2013481","journal-title":"Ann Rheum Dis"},{"key":"3874_CR21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D et al (2015) Pathogenesis of systemic sclerosis. Front Immunol 6:272","journal-title":"Front Immunol"},{"issue":"4","key":"3874_CR22","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2353\/ajpath.2010.090593","volume":"176","author":"Y Asano","year":"2010","unstructured":"Asano Y et al (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176(4):1983\u20131998","journal-title":"Am J Pathol"},{"issue":"5","key":"3874_CR23","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/art.38326","volume":"66","author":"M Kuwana","year":"2014","unstructured":"Kuwana M, Okazaki Y (2014) Brief report: impaired in vivo neovascularization capacity of endothelial progenitor cells in patients with systemic sclerosis. Arthritis Rheumatol 66(5):1300\u20131305","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"3874_CR24","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1186\/ar3180","volume":"12","author":"Y Yamaguchi","year":"2010","unstructured":"Yamaguchi Y et al (2010) Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Res Ther 12(6):R205","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3874_CR25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1172\/JCI93557","volume":"128","author":"J Herrera","year":"2018","unstructured":"Herrera J, Henke CA, Bitterman PB (2018) Extracellular matrix as a driver of progressive fibrosis. J Clin Invest 128(1):45\u201353","journal-title":"J Clin Invest"},{"issue":"6","key":"3874_CR26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD et al (2013) An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733\u2013748","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3874_CR27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.cell.2017.07.034","volume":"170","author":"JA Zepp","year":"2017","unstructured":"Zepp JA et al (2017) Distinct mesenchymal lineages and niches promote epithelial self-renewal and myofibrogenesis in the lung. Cell 170(6):1134\u20131148","journal-title":"Cell"},{"key":"3874_CR28","doi-asserted-by":"crossref","first-page":"607483","DOI":"10.3389\/fcell.2020.607483","volume":"8","author":"J Di Gregorio","year":"2020","unstructured":"Di Gregorio J et al (2020) The epithelial-to-mesenchymal transition as a possible therapeutic target in fibrotic disorders. Front Cell Dev Biol 8:607483","journal-title":"Front Cell Dev Biol"},{"key":"3874_CR29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmed.2017.00154","volume":"4","author":"A Kaur","year":"2017","unstructured":"Kaur A, Mathai SK, Schwartz DA (2017) Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med (Lausanne) 4:154","journal-title":"Front Med (Lausanne)"},{"issue":"16","key":"3874_CR30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa1013660","volume":"364","author":"MA Seibold","year":"2011","unstructured":"Seibold MA et al (2011) A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364(16):1503\u20131512","journal-title":"N Engl J Med"},{"issue":"10","key":"3874_CR31","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1164\/rccm.201509-1863OC","volume":"193","author":"SK Mathai","year":"2016","unstructured":"Mathai SK et al (2016) Desmoplakin variants are associated with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 193(10):1151\u20131160","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"3874_CR32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","volume":"5","author":"RJ Allen","year":"2017","unstructured":"Allen RJ et al (2017) Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respir Med 5(11):869\u2013880","journal-title":"Lancet Respir Med"},{"issue":"8","key":"3874_CR33","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1056\/NEJM200102223440805","volume":"344","author":"LM Nogee","year":"2001","unstructured":"Nogee LM et al (2001) A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344(8):573\u2013579","journal-title":"N Engl J Med"},{"issue":"8","key":"3874_CR34","doi-asserted-by":"crossref","first-page":"L721","DOI":"10.1152\/ajplung.00410.2011","volume":"302","author":"H Tanjore","year":"2012","unstructured":"Tanjore H, Blackwell TS, Lawson WE (2012) Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 302(8):L721\u2013L729","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"26","key":"3874_CR35","doi-asserted-by":"crossref","first-page":"10562","DOI":"10.1073\/pnas.1107559108","volume":"108","author":"WE Lawson","year":"2011","unstructured":"Lawson WE et al (2011) Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 108(26):10562\u201310567","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"3874_CR36","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa066157","volume":"356","author":"MY Armanios","year":"2007","unstructured":"Armanios MY et al (2007) Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356(13):1317\u20131326","journal-title":"N Engl J Med"},{"issue":"18","key":"3874_CR37","doi-asserted-by":"crossref","first-page":"7552","DOI":"10.1073\/pnas.0701009104","volume":"104","author":"KD Tsakiri","year":"2007","unstructured":"Tsakiri KD et al (2007) Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 104(18):7552\u20137557","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6963","key":"3874_CR38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nature02118","volume":"426","author":"FA di Fagagna","year":"2003","unstructured":"di Fagagna FA et al (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426(6963):194\u2013198","journal-title":"Nature"},{"issue":"1","key":"3874_CR39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0092-8674(01)00504-9","volume":"107","author":"MT Hemann","year":"2001","unstructured":"Hemann MT et al (2001) The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 107(1):67\u201377","journal-title":"Cell"},{"issue":"1","key":"3874_CR40","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1378\/chest.13-2224","volume":"146","author":"JA Kropski","year":"2014","unstructured":"Kropski JA et al (2014) A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 146(1):e1\u2013e7","journal-title":"Chest"},{"issue":"12","key":"3874_CR41","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/ng.3423","volume":"47","author":"DH Moon","year":"2015","unstructured":"Moon DH et al (2015) Poly(A)-specific ribonuclease (PARN) mediates 3\u2019-end maturation of the telomerase RNA component. Nat Genet 47(12):1482\u20131488","journal-title":"Nat Genet"},{"issue":"6","key":"3874_CR42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1164\/rccm.201408-1510OC","volume":"191","author":"JD Cogan","year":"2015","unstructured":"Cogan JD et al (2015) Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 191(6):646\u2013655","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3874_CR43","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1378\/chest.14-1947","volume":"147","author":"JK Alder","year":"2015","unstructured":"Alder JK et al (2015) Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 147(5):1361\u20131368","journal-title":"Chest"},{"issue":"17","key":"3874_CR44","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0960-9822(03)00542-6","volume":"13","author":"H Takai","year":"2003","unstructured":"Takai H, Smogorzewska A, de Lange T (2003) DNA damage foci at dysfunctional telomeres. Curr Biol 13(17):1549\u20131556","journal-title":"Curr Biol"},{"key":"3874_CR45","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ncomms1708","volume":"3","author":"G Hewitt","year":"2012","unstructured":"Hewitt G et al (2012) Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 3:708","journal-title":"Nat Commun"},{"issue":"16","key":"3874_CR46","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1073\/pnas.1504780112","volume":"112","author":"JK Alder","year":"2015","unstructured":"Alder JK et al (2015) Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci USA 112(16):5099\u20135104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"14","key":"3874_CR47","doi-asserted-by":"crossref","first-page":"e86704","DOI":"10.1172\/jci.insight.86704","volume":"1","author":"RP Naikawadi","year":"2016","unstructured":"Naikawadi RP et al (2016) Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. JCI Insight 1(14):e86704","journal-title":"JCI Insight"},{"key":"3874_CR48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.31299","author":"JM Povedano","year":"2018","unstructured":"Povedano JM et al (2018) Therapeutic effects of telomerase in mice with pulmonary fibrosis induced by damage to the lungs and short telomeres. Elife. https:\/\/doi.org\/10.7554\/eLife.31299","journal-title":"Elife"},{"issue":"6","key":"3874_CR49","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1183\/13993003.00308-2016","volume":"48","author":"CA Newton","year":"2016","unstructured":"Newton CA et al (2016) Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 48(6):1710\u20131720","journal-title":"Eur Respir J"},{"issue":"4","key":"3874_CR50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.200210-1165OC","volume":"168","author":"A Xaubet","year":"2003","unstructured":"Xaubet A et al (2003) Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168(4):431\u2013435","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"3874_CR51","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1164\/rccm.201304-0760OC","volume":"188","author":"DN O'Dwyer","year":"2013","unstructured":"O\u2019Dwyer DN et al (2013) The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 188(12):1442\u20131450","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3874_CR52","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00251-012-0604-6","volume":"64","author":"NM Korthagen","year":"2012","unstructured":"Korthagen NM et al (2012) IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 64(5):371\u2013377","journal-title":"Immunogenetics"},{"key":"3874_CR53","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2019.02025","volume":"10","author":"D Xu","year":"2019","unstructured":"Xu D, Mu R, Wei X (2019) The roles of il-1 family cytokines in the pathogenesis of systemic sclerosis. Front Immunol 10:2025","journal-title":"Front Immunol"},{"key":"3874_CR54","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1465-9921-12-73","volume":"12","author":"MH Ahn","year":"2011","unstructured":"Ahn MH et al (2011) A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir Res 12:73","journal-title":"Respir Res"},{"issue":"2","key":"3874_CR55","doi-asserted-by":"crossref","first-page":"e14715","DOI":"10.1371\/journal.pone.0014715","volume":"6","author":"J Xue","year":"2011","unstructured":"Xue J et al (2011) The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLOS ONE 6(2):e14715","journal-title":"PLOS ONE"},{"issue":"6","key":"3874_CR56","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3390\/jcm9061993","volume":"9","author":"C Caliskan","year":"2020","unstructured":"Caliskan C et al (2020) Genetic variation in CCL18 gene influences CCL18 expression and correlates with survival in idiopathic pulmonary fibrosis-part B. J Clin Med 9(6):1993","journal-title":"J Clin Med"},{"issue":"3","key":"3874_CR57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.rdc.2015.04.001","volume":"41","author":"G Salazar","year":"2015","unstructured":"Salazar G, Mayes MD (2015) Genetics, epigenetics, and genomics of systemic sclerosis. Rheum Dis Clin North Am 41(3):345\u2013366","journal-title":"Rheum Dis Clin North Am"},{"issue":"4","key":"3874_CR58","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1378\/chest.14-1299","volume":"147","author":"KA Johannson","year":"2015","unstructured":"Johannson KA, Balmes JR, Collard HR (2015) Air pollution exposure: a novel environmental risk factor for interstitial lung disease? Chest 147(4):1161\u20131167","journal-title":"Chest"},{"issue":"3","key":"3874_CR59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1513\/pats.201112-055AW","volume":"9","author":"K Macneal","year":"2012","unstructured":"Macneal K, Schwartz DA (2012) The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc 9(3):120\u2013125","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"3874_CR60","doi-asserted-by":"crossref","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M et al (2016) Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLOS ONE 11(3):e0151425","journal-title":"PLOS ONE"},{"issue":"38","key":"3874_CR61","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.3748\/wjg.14.5880","volume":"14","author":"Y Arase","year":"2008","unstructured":"Arase Y et al (2008) Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis. World J Gastroenterol 14(38):5880\u20135886","journal-title":"World J Gastroenterol"},{"issue":"12","key":"3874_CR62","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1164\/rccm.201010-1752OC","volume":"183","author":"SC Wootton","year":"2011","unstructured":"Wootton SC et al (2011) Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183(12):1698\u20131702","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3874_CR63","doi-asserted-by":"crossref","first-page":"L257","DOI":"10.1152\/ajplung.00238.2020","volume":"320","author":"LT McDonald","year":"2021","unstructured":"McDonald LT (2021) Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 320(2):L257\u2013L265","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"2","key":"3874_CR64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.stem.2014.07.012","volume":"15","author":"BL Hogan","year":"2014","unstructured":"Hogan BL et al (2014) Repair and regeneration of the respiratory system: complexity, plasticity, and mechanisms of lung stem cell function. Cell Stem Cell 15(2):123\u2013138","journal-title":"Cell Stem Cell"},{"issue":"6380","key":"3874_CR65","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1126\/science.aam6603","volume":"359","author":"AN Nabhan","year":"2018","unstructured":"Nabhan AN et al (2018) Single-cell Wnt signaling niches maintain stemness of alveolar type 2 cells. Science 359(6380):1118\u20131123","journal-title":"Science"},{"issue":"7491","key":"3874_CR66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nature12930","volume":"507","author":"TJ Desai","year":"2014","unstructured":"Desai TJ, Brownfield DG, Krasnow MA (2014) Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507(7491):190\u2013194","journal-title":"Nature"},{"issue":"7695","key":"3874_CR67","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature25786","volume":"555","author":"WJ Zacharias","year":"2018","unstructured":"Zacharias WJ et al (2018) Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor. Nature 555(7695):251\u2013255","journal-title":"Nature"},{"issue":"4","key":"3874_CR68","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1513\/pats.200601-003TK","volume":"3","author":"M Selman","year":"2006","unstructured":"Selman M, Pardo A (2006) Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 3(4):364\u2013372","journal-title":"Proc Am Thorac Soc"},{"issue":"7","key":"3874_CR69","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1172\/JCI68782","volume":"123","author":"CE Barkauskas","year":"2013","unstructured":"Barkauskas CE et al (2013) Type 2 alveolar cells are stem cells in adult lung. J Clin Invest 123(7):3025\u20133036","journal-title":"J Clin Invest"},{"issue":"20","key":"3874_CR70","first-page":"e90558","volume":"1","author":"Y Xu","year":"2016","unstructured":"Xu Y et al (2016) Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. JCI Insight 1(20):e90558","journal-title":"JCI Insight"},{"issue":"3","key":"3874_CR71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.200810-1615OC","volume":"181","author":"TH Sisson","year":"2010","unstructured":"Sisson TH et al (2010) Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181(3):254\u2013263","journal-title":"Am J Respir Crit Care Med"},{"key":"3874_CR72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.202004-1274OC","volume":"203","author":"C Yao","year":"2020","unstructured":"Yao C et al (2020) Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. Am J Respir Crit Care Med 203:707","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3874_CR73","first-page":"610","volume":"42","author":"R Urbanczik","year":"1988","unstructured":"Urbanczik R (1988) Problems in relation to chemotherapy of mycobacterioses caused by so-called atypical mycobacteria. Prax Klin Pneumol 42(7):610\u2013612","journal-title":"Prax Klin Pneumol"},{"issue":"1","key":"3874_CR74","doi-asserted-by":"crossref","first-page":"242","DOI":"10.18632\/aging.102613","volume":"12","author":"X Chen","year":"2019","unstructured":"Chen X et al (2019) Epithelial cell senescence induces pulmonary fibrosis through Nanog-mediated fibroblast activation. Aging (Albany NY) 12(1):242\u2013259","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"3874_CR75","doi-asserted-by":"crossref","first-page":"e12858","DOI":"10.1111\/acel.12858","volume":"18","author":"Y Tian","year":"2019","unstructured":"Tian Y et al (2019) Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF-kappaB activation. Aging Cell 18(1):e12858","journal-title":"Aging Cell"},{"issue":"3","key":"3874_CR76","doi-asserted-by":"crossref","first-page":"L391","DOI":"10.1152\/ajplung.00097.2010","volume":"300","author":"S Minagawa","year":"2011","unstructured":"Minagawa S et al (2011) Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-beta-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 300(3):L391-401","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"3874_CR77","doi-asserted-by":"crossref","first-page":"L409","DOI":"10.1152\/ajplung.00032.2013","volume":"305","author":"L Zhao","year":"2013","unstructured":"Zhao L, Yee M, O\u2019Reilly MA (2013) Transdifferentiation of alveolar epithelial type II to type I cells is controlled by opposing TGF-beta and BMP signaling. Am J Physiol Lung Cell Mol Physiol 305(6):L409\u2013L418","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"3874_CR78","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.celrep.2019.02.046","volume":"26","author":"J Finn","year":"2019","unstructured":"Finn J et al (2019) Dlk1-mediated temporal regulation of notch signaling is required for differentiation of alveolar type II to type I cells during repair. Cell Rep 26(11):2942\u20132954","journal-title":"Cell Rep"},{"issue":"1","key":"3874_CR79","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1038\/s41467-020-17358-3","volume":"11","author":"M Strunz","year":"2020","unstructured":"Strunz M et al (2020) Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis. Nat Commun 11(1):3559","journal-title":"Nat Commun"},{"issue":"28","key":"3874_CR80","doi-asserted-by":"crossref","first-page":"eaba1983","DOI":"10.1126\/sciadv.aba1983","volume":"6","author":"TS Adams","year":"2020","unstructured":"Adams TS et al (2020) Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv 6(28):eaba1983","journal-title":"Sci Adv"},{"issue":"35","key":"3874_CR81","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1073\/pnas.0605669103","volume":"103","author":"KK Kim","year":"2006","unstructured":"Kim KK et al (2006) Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 103(35):13180\u201313185","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"3874_CR82","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0002-9440(10)62351-6","volume":"166","author":"BC Willis","year":"2005","unstructured":"Willis BC et al (2005) Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166(5):1321\u20131332","journal-title":"Am J Pathol"},{"issue":"3","key":"3874_CR83","doi-asserted-by":"crossref","first-page":"L525","DOI":"10.1152\/ajplung.00163.2007","volume":"293","author":"BC Willis","year":"2007","unstructured":"Willis BC, Borok Z (2007) TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 293(3):L525\u2013L534","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"52","key":"3874_CR84","first-page":"E1475","volume":"108","author":"JR Rock","year":"2011","unstructured":"Rock JR et al (2011) Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 108(52):E1475\u2013E1483","journal-title":"Proc Natl Acad Sci USA"},{"issue":"22","key":"3874_CR85","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.C800074200","volume":"283","author":"M Korpal","year":"2008","unstructured":"Korpal M et al (2008) The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283(22):14910\u201314914","journal-title":"J Biol Chem"},{"issue":"5","key":"3874_CR86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","volume":"10","author":"PA Gregory","year":"2008","unstructured":"Gregory PA et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10(5):593\u2013601","journal-title":"Nat Cell Biol"},{"issue":"2","key":"3874_CR87","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/rccm.200911-1698OC","volume":"182","author":"KV Pandit","year":"2010","unstructured":"Pandit KV et al (2010) Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 182(2):220\u2013229","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3874_CR88","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trsl.2011.01.012","volume":"157","author":"KV Pandit","year":"2011","unstructured":"Pandit KV, Milosevic J, Kaminski N (2011) MicroRNAs in idiopathic pulmonary fibrosis. Transl Res 157(4):191\u2013199","journal-title":"Transl Res"},{"issue":"2","key":"3874_CR89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/reg2.77","volume":"4","author":"AL Mescher","year":"2017","unstructured":"Mescher AL (2017) Macrophages and fibroblasts during inflammation and tissue repair in models of organ regeneration. Regeneration (Oxf) 4(2):39\u201353","journal-title":"Regeneration (Oxf)"},{"issue":"5","key":"3874_CR90","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.freeradbiomed.2010.04.036","volume":"49","author":"CR Kliment","year":"2010","unstructured":"Kliment CR, Oury TD (2010) Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 49(5):707\u2013717","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3874_CR91","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12931-018-0754-7","volume":"19","author":"AG Fois","year":"2018","unstructured":"Fois AG et al (2018) Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: a systematic review. Respir Res 19(1):51","journal-title":"Respir Res"},{"issue":"10","key":"3874_CR92","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/bmm-2018-0108","volume":"12","author":"P Paliogiannis","year":"2018","unstructured":"Paliogiannis P et al (2018) Oxidative stress-linked biomarkers in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Biomark Med 12(10):1175\u20131184","journal-title":"Biomark Med"},{"issue":"1","key":"3874_CR93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2009.09.026","volume":"48","author":"RM Liu","year":"2010","unstructured":"Liu RM, Gaston Pravia KA (2010) Oxidative stress and glutathione in TGF-beta-mediated fibrogenesis. Free Radic Biol Med 48(1):1\u201315","journal-title":"Free Radic Biol Med"},{"issue":"9","key":"3874_CR94","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/nm.2005","volume":"15","author":"L Hecker","year":"2009","unstructured":"Hecker L et al (2009) NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 15(9):1077\u20131081","journal-title":"Nat Med"},{"issue":"7","key":"3874_CR95","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1074\/jbc.M116.752261","volume":"292","author":"K Bernard","year":"2017","unstructured":"Bernard K et al (2017) NADPH oxidase 4 (Nox4) suppresses mitochondrial biogenesis and bioenergetics in lung fibroblasts via a nuclear factor erythroid-derived 2-like 2 (Nrf2)-dependent pathway. J Biol Chem 292(7):3029\u20133038","journal-title":"J Biol Chem"},{"issue":"22","key":"3874_CR96","doi-asserted-by":"crossref","first-page":"10805","DOI":"10.1158\/0008-5472.CAN-06-1236","volume":"66","author":"A Dasari","year":"2006","unstructured":"Dasari A et al (2006) Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase\/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66(22):10805\u201310814","journal-title":"Cancer Res"},{"issue":"9","key":"3874_CR97","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrm2233","volume":"8","author":"J Campisi","year":"2007","unstructured":"Campisi J, di Fagagna Fd\u2019A (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8(9):729\u201340","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"3874_CR98","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0531-5565(00)00180-7","volume":"35","author":"O Toussaint","year":"2000","unstructured":"Toussaint O, Medrano EE, von Zglinicki T (2000) Cellular and molecular mechanisms of stress-induced premature senescence (SIPS) of human diploid fibroblasts and melanocytes. Exp Gerontol 35(8):927\u2013945","journal-title":"Exp Gerontol"},{"issue":"3","key":"3874_CR99","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbamcr.2013.11.015","volume":"1843","author":"IH Ng","year":"2014","unstructured":"Ng IH et al (2014) Oxidative stress impairs multiple regulatory events to drive persistent cytokine-stimulated STAT3 phosphorylation. Biochim Biophys Acta 1843(3):483\u2013494","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3874_CR100","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1165\/rcmb.2002-0262OC","volume":"29","author":"YP Moodley","year":"2003","unstructured":"Moodley YP et al (2003) Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol 29(4):490\u2013498","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"3874_CR101","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nm.4447","volume":"24","author":"G Yu","year":"2018","unstructured":"Yu G et al (2018) Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function. Nat Med 24(1):39\u201349","journal-title":"Nat Med"},{"issue":"8","key":"3874_CR102","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","volume":"16","author":"Y Mostmans","year":"2017","unstructured":"Mostmans Y et al (2017) The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmun Rev 16(8):774\u2013786","journal-title":"Autoimmun Rev"},{"key":"3874_CR103","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.matbio.2016.01.012","volume":"51","author":"SA Jimenez","year":"2016","unstructured":"Jimenez SA, Piera-Velazquez S (2016) Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of systemic sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? Matrix Biol 51:26\u201336","journal-title":"Matrix Biol"},{"issue":"2","key":"3874_CR104","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1074\/jbc.M112.431973","volume":"288","author":"M Jain","year":"2013","unstructured":"Jain M et al (2013) Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. J Biol Chem 288(2):770\u2013777","journal-title":"J Biol Chem"},{"key":"3874_CR105","doi-asserted-by":"crossref","first-page":"11853","DOI":"10.1038\/ncomms11853","volume":"7","author":"SM Evrard","year":"2016","unstructured":"Evrard SM et al (2016) Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat Commun 7:11853","journal-title":"Nat Commun"},{"key":"3874_CR106","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fphar.2017.00473","volume":"8","author":"Z Ma","year":"2017","unstructured":"Ma Z et al (2017) Lovastatin alleviates endothelial-to-mesenchymal transition in glomeruli via suppression of oxidative stress and TGF-beta1 signaling. Front Pharmacol 8:473","journal-title":"Front Pharmacol"},{"issue":"3","key":"3874_CR107","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20101500","volume":"437","author":"D Medici","year":"2011","unstructured":"Medici D, Potenta S, Kalluri R (2011) Transforming growth factor-beta2 promotes snail-mediated endothelial-mesenchymal transition through convergence of smad-dependent and smad-independent signalling. Biochem J 437(3):515\u2013520","journal-title":"Biochem J"},{"issue":"1","key":"3874_CR108","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/cr.2008.326","volume":"19","author":"MJ Goumans","year":"2009","unstructured":"Goumans MJ, Liu Z, ten Dijke P (2009) TGF-beta signaling in vascular biology and dysfunction. Cell Res 19(1):116\u2013127","journal-title":"Cell Res"},{"issue":"Suppl 1","key":"3874_CR109","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1755-1536-5-S1-S7","volume":"5","author":"S Piera-Velazquez","year":"2012","unstructured":"Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 5(Suppl 1):S7","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"5","key":"3874_CR110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00018-008-8465-8","volume":"66","author":"C Vandewalle","year":"2009","unstructured":"Vandewalle C, Van Roy F, Berx G (2009) The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci 66(5):773\u2013787","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"3874_CR111","doi-asserted-by":"crossref","first-page":"e0161988","DOI":"10.1371\/journal.pone.0161988","volume":"11","author":"PJ Wermuth","year":"2016","unstructured":"Wermuth PJ et al (2016) Stimulation of transforming growth factor-beta1-induced endothelial-to-mesenchymal transition and tissue fibrosis by endothelin-1 (ET-1): a novel profibrotic effect of ET-1. PLOS ONE 11(9):e0161988","journal-title":"PLOS ONE"},{"key":"3874_CR112","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3389\/fimmu.2018.01985","volume":"9","author":"DTB Thuan","year":"2018","unstructured":"Thuan DTB et al (2018) A potential link between oxidative stress and endothelial-to-mesenchymal transition in systemic sclerosis. Front Immunol 9:1985","journal-title":"Front Immunol"},{"issue":"9","key":"3874_CR113","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/art.23791","volume":"58","author":"F Del Galdo","year":"2008","unstructured":"Del Galdo F et al (2008) Decreased expression of caveolin 1 in patients with systemic sclerosis: crucial role in the pathogenesis of tissue fibrosis. Arthritis Rheum 58(9):2854\u20132865","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3874_CR114","doi-asserted-by":"crossref","first-page":"L843","DOI":"10.1152\/ajplung.00295.2007","volume":"294","author":"E Tourkina","year":"2008","unstructured":"Tourkina E et al (2008) Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol 294(5):L843\u2013L861","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"13","key":"3874_CR115","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1084\/jem.20061536","volume":"203","author":"XM Wang","year":"2006","unstructured":"Wang XM et al (2006) Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J Exp Med 203(13):2895\u20132906","journal-title":"J Exp Med"},{"issue":"29","key":"3874_CR116","doi-asserted-by":"crossref","first-page":"19452","DOI":"10.1074\/jbc.M109.011833","volume":"284","author":"Y Fu","year":"2009","unstructured":"Fu Y et al (2009) Differential regulation of transforming growth factor beta signaling pathways by notch in human endothelial cells. J Biol Chem 284(29):19452\u201319462","journal-title":"J Biol Chem"},{"issue":"8","key":"3874_CR117","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei J et al (2012) Wnt\/beta-catenin signaling is hyperactivated in systemic sclerosis and induces smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 64(8):2734\u20132745","journal-title":"Arthritis Rheum"},{"key":"3874_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98850","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S et al (2018) TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.98850","journal-title":"JCI Insight"},{"key":"3874_CR119","doi-asserted-by":"crossref","first-page":"11703","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya S et al (2016) Tenascin-C drives persistence of organ fibrosis. Nat Commun 7:11703","journal-title":"Nat Commun"},{"issue":"232","key":"3874_CR120","doi-asserted-by":"crossref","first-page":"232ra50","DOI":"10.1126\/scitranslmed.3008264","volume":"6","author":"S Bhattacharyya","year":"2014","unstructured":"Bhattacharyya S et al (2014) FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med 6(232):232ra50","journal-title":"Sci Transl Med"},{"issue":"9","key":"3874_CR121","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1074\/jbc.M306818200","volume":"279","author":"F Novi","year":"2004","unstructured":"Novi F et al (2004) The paired activation of the two components of the muscarinic M3 receptor dimer is required for induction of ERK1\/2 phosphorylation. J Biol Chem 279(9):7476\u20137486","journal-title":"J Biol Chem"},{"issue":"12","key":"3874_CR122","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1111\/jcmm.12419","volume":"18","author":"LC Li","year":"2014","unstructured":"Li LC, Gao J, Li J (2014) Emerging role of HMGB1 in fibrotic diseases. J Cell Mol Med 18(12):2331\u20132339","journal-title":"J Cell Mol Med"},{"issue":"11","key":"3874_CR123","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm1315","volume":"11","author":"D Jiang","year":"2005","unstructured":"Jiang D et al (2005) Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11(11):1173\u20131179","journal-title":"Nat Med"},{"key":"3874_CR124","doi-asserted-by":"crossref","unstructured":"Ah Kioon, M.D., et al., Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8. Sci Transl Med, 2018. 10(423).","DOI":"10.1126\/scitranslmed.aam8458"},{"issue":"8","key":"3874_CR125","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/art.39655","volume":"68","author":"F Fang","year":"2016","unstructured":"Fang F et al (2016) Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor beta-dependent fibroblast activation. Arthritis Rheumatol 68(8):1989\u20132002","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"3874_CR126","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.30568","volume":"63","author":"CM Artlett","year":"2011","unstructured":"Artlett CM et al (2011) The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum 63(11):3563\u20133574","journal-title":"Arthritis Rheum"},{"issue":"9","key":"3874_CR127","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton CP et al (2018) Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the fasscinate clinical trial in systemic sclerosis. Ann Rheum Dis 77(9):1362\u20131371","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3874_CR128","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12931-020-1319-0","volume":"21","author":"G Epstein Shochet","year":"2020","unstructured":"Epstein Shochet G et al (2020) TGF-beta pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir Res 21(1):56","journal-title":"Respir Res"},{"issue":"2","key":"3874_CR129","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna D et al (2018) Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (fasscinate). Ann Rheum Dis 77(2):212\u2013220","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"3874_CR130","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/art.39797","volume":"68","author":"FV Castelino","year":"2016","unstructured":"Castelino FV et al (2016) An Autotaxin\/lysophosphatidic acid\/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis Rheumatol 68(12):2964\u20132974","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"3874_CR131","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201712-2410OC","volume":"199","author":"PA Reyfman","year":"2019","unstructured":"Reyfman PA et al (2019) Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. Am J Respir Crit Care Med 199(12):1517\u20131536","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3874_CR132","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v7.i4.231","volume":"7","author":"N Duru","year":"2016","unstructured":"Duru N, Wolfson B, Zhou Q (2016) Mechanisms of the alternative activation of macrophages and non-coding RNAs in the development of radiation-induced lung fibrosis. World J Biol Chem 7(4):231\u2013239","journal-title":"World J Biol Chem"},{"issue":"12","key":"3874_CR133","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","volume":"79","author":"Y Allanore","year":"2020","unstructured":"Allanore Y et al (2020) A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis 79(12):1600\u20131607","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3874_CR134","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0000000000000644","volume":"31","author":"S Pillai","year":"2019","unstructured":"Pillai S (2019) T and B lymphocytes in fibrosis and systemic sclerosis. Curr Opin Rheumatol 31(6):576\u2013581","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"3874_CR135","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76(8):1327\u20131339","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"3874_CR136","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3899\/jrheum.180441","volume":"46","author":"ER Volkmann","year":"2019","unstructured":"Volkmann ER et al (2019) Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II. J Rheumatol 46(10):1316\u20131325","journal-title":"J Rheumatol"},{"issue":"3","key":"3874_CR137","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.12.1330","volume":"138","author":"H Mattoo","year":"2016","unstructured":"Mattoo H et al (2016) Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 138(3):825\u2013838","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3874_CR138","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jaci.2020.05.022","volume":"147","author":"CA Perugino","year":"2021","unstructured":"Perugino CA et al (2021) CD4(+) and CD8(+) cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. J Allergy Clin Immunol 147(1):368\u2013382","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3874_CR139","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","volume":"130","author":"T Maehara","year":"2020","unstructured":"Maehara T et al (2020) Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. J Clin Invest 130(5):2451\u20132464","journal-title":"J Clin Invest"},{"issue":"3","key":"3874_CR140","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4049\/jimmunol.2000433","volume":"206","author":"H Allard-Chamard","year":"2021","unstructured":"Allard-Chamard H et al (2021) CD4(+)CTLs in fibrosing mediastinitis linked to histoplasma capsulatum. J Immunol 206(3):524\u2013530","journal-title":"J Immunol"},{"issue":"431","key":"3874_CR141","doi-asserted-by":"crossref","first-page":"eaaf5307","DOI":"10.1126\/scitranslmed.aaf5307","volume":"10","author":"DK Taylor","year":"2018","unstructured":"Taylor DK et al (2018) T follicular helper-like cells contribute to skin fibrosis. Sci Transl Med 10(431):eaaf5307","journal-title":"Sci Transl Med"},{"issue":"4","key":"3874_CR142","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","volume":"78","author":"L Ricard","year":"2019","unstructured":"Ricard L et al (2019) Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib. Ann Rheum Dis 78(4):539\u2013550","journal-title":"Ann Rheum Dis"},{"key":"3874_CR143","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","volume":"209","author":"B Korman","year":"2019","unstructured":"Korman B (2019) Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis. Transl Res 209:77\u201389","journal-title":"Transl Res"},{"issue":"2","key":"3874_CR144","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.stem.2016.10.004","volume":"20","author":"E El Agha","year":"2017","unstructured":"El Agha E et al (2017) Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell 20(2):261\u2013273","journal-title":"Cell Stem Cell"},{"issue":"12","key":"3874_CR145","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson NC et al (2013) Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 19(12):1617\u20131624","journal-title":"Nat Med"},{"issue":"8","key":"3874_CR146","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1172\/JCI85328","volume":"126","author":"T Xie","year":"2016","unstructured":"Xie T et al (2016) Transcription factor TBX4 regulates myofibroblast accumulation and lung fibrosis. J Clin Invest 126(8):3063\u20133079","journal-title":"J Clin Invest"},{"issue":"8","key":"3874_CR147","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.2848","volume":"18","author":"S Dulauroy","year":"2012","unstructured":"Dulauroy S et al (2012) Lineage tracing and genetic ablation of ADAM12(+) perivascular cells identify a major source of profibrotic cells during acute tissue injury. Nat Med 18(8):1262\u20131270","journal-title":"Nat Med"},{"issue":"2","key":"3874_CR148","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40139-017-0134-x","volume":"5","author":"DM Habiel","year":"2017","unstructured":"Habiel DM, Hogaboam CM (2017) Heterogeneity of fibroblasts and myofibroblasts in pulmonary fibrosis. Curr Pathobiol Rep 5(2):101\u2013110","journal-title":"Curr Pathobiol Rep"},{"issue":"9","key":"3874_CR149","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1164\/rccm.201204-0754OC","volume":"186","author":"AJ Booth","year":"2012","unstructured":"Booth AJ et al (2012) Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am J Respir Crit Care Med 186(9):866\u2013876","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"3874_CR150","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1172\/JCI71386","volume":"124","author":"MW Parker","year":"2014","unstructured":"Parker MW et al (2014) Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest 124(4):1622\u20131635","journal-title":"J Clin Invest"},{"issue":"1","key":"3874_CR151","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41467-019-08831-9","volume":"10","author":"I Angelidis","year":"2019","unstructured":"Angelidis I et al (2019) An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. Nat Commun 10(1):963","journal-title":"Nat Commun"},{"issue":"1","key":"3874_CR152","doi-asserted-by":"crossref","first-page":"1601805","DOI":"10.1183\/13993003.01805-2016","volume":"50","author":"G Burgstaller","year":"2017","unstructured":"Burgstaller G et al (2017) The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J 50(1):1601805","journal-title":"Eur Respir J"},{"key":"3874_CR153","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jprot.2018.02.027","volume":"189","author":"E Ahrman","year":"2018","unstructured":"Ahrman E et al (2018) Quantitative proteomic characterization of the lung extracellular matrix in chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. J Proteomics 189:23\u201333","journal-title":"J Proteomics"},{"issue":"1","key":"3874_CR154","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI93561","volume":"128","author":"DJ Tschumperlin","year":"2018","unstructured":"Tschumperlin DJ et al (2018) Mechanosensing and fibrosis. J Clin Invest 128(1):74\u201384","journal-title":"J Clin Invest"},{"issue":"516","key":"3874_CR155","doi-asserted-by":"crossref","first-page":"eaau6296","DOI":"10.1126\/scitranslmed.aau6296","volume":"11","author":"AJ Haak","year":"2019","unstructured":"Haak AJ et al (2019) Selective YAP\/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis. Sci Transl Med 11(516):eaau6296","journal-title":"Sci Transl Med"},{"issue":"2","key":"3874_CR156","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1165\/rcmb.2013-0094TR","volume":"49","author":"BB Moore","year":"2013","unstructured":"Moore BB et al (2013) Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 49(2):167\u2013179","journal-title":"Am J Respir Cell Mol Biol"},{"key":"3874_CR157","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.matbio.2018.03.014","volume":"68\u201369","author":"G Yu","year":"2018","unstructured":"Yu G, Ibarra GH, Kaminski N (2018) Fibrosis: lessons from OMICS analyses of the human lung. Matrix Biol 68\u201369:422\u2013434","journal-title":"Matrix Biol"},{"issue":"4","key":"3874_CR158","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1513\/pats.200601-011TK","volume":"3","author":"N Kaminski","year":"2006","unstructured":"Kaminski N, Rosas IO (2006) Gene expression profiling as a window into idiopathic pulmonary fibrosis pathogenesis: can we identify the right target genes? Proc Am Thorac Soc 3(4):339\u2013344","journal-title":"Proc Am Thorac Soc"},{"issue":"3","key":"3874_CR159","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1371\/journal.pmed.0050062","volume":"5","author":"M Selman","year":"2008","unstructured":"Selman M, Pardo A, Kaminski N (2008) Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 5(3):e62","journal-title":"PLoS Med"},{"issue":"2","key":"3874_CR160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI74942","volume":"125","author":"M Bueno","year":"2015","unstructured":"Bueno M et al (2015) PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest 125(2):521\u2013538","journal-title":"J Clin Invest"},{"issue":"12","key":"3874_CR161","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/thoraxjnl-2012-202943","volume":"68","author":"IV Yang","year":"2013","unstructured":"Yang IV et al (2013) Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68(12):1114\u20131121","journal-title":"Thorax"},{"issue":"2","key":"3874_CR162","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.200504-644OC","volume":"173","author":"M Selman","year":"2006","unstructured":"Selman M et al (2006) Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 173(2):188\u2013198","journal-title":"Am J Respir Crit Care Med"},{"issue":"7718","key":"3874_CR163","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41586-018-0393-7","volume":"560","author":"DT Montoro","year":"2018","unstructured":"Montoro DT et al (2018) A revised airway epithelial hierarchy includes CFTR-expressing ionocytes. Nature 560(7718):319\u2013324","journal-title":"Nature"},{"issue":"7718","key":"3874_CR164","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41586-018-0394-6","volume":"560","author":"LW Plasschaert","year":"2018","unstructured":"Plasschaert LW et al (2018) A single-cell atlas of the airway epithelium reveals the CFTR-rich pulmonary ionocyte. Nature 560(7718):377\u2013381","journal-title":"Nature"},{"key":"3874_CR165","doi-asserted-by":"crossref","first-page":"e27041","DOI":"10.7554\/eLife.27041","volume":"6","author":"A Regev","year":"2017","unstructured":"Regev A et al (2017) The human cell atlas. Elife 6:e27041","journal-title":"Elife"},{"issue":"2","key":"3874_CR166","doi-asserted-by":"crossref","first-page":"1802441","DOI":"10.1183\/13993003.02441-2018","volume":"54","author":"C Morse","year":"2019","unstructured":"Morse C et al (2019) Proliferating SPP1\/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J 54(2):1802441","journal-title":"Eur Respir J"},{"issue":"26","key":"3874_CR167","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380(26):2518\u20132528","journal-title":"N Engl J Med"},{"key":"3874_CR168","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3389\/fimmu.2018.02390","volume":"9","author":"N Del Papa","year":"2018","unstructured":"Del Papa N et al (2018) Autologous hematopoietic stem cell transplantation for treatment of systemic sclerosis. Front Immunol 9:2390","journal-title":"Front Immunol"},{"issue":"1","key":"3874_CR169","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","volume":"186","author":"I Noth","year":"2012","unstructured":"Noth I et al (2012) A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 186(1):88\u201395","journal-title":"Am J Respir Crit Care Med"},{"issue":"22","key":"3874_CR170","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L et al (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071\u20132082","journal-title":"N Engl J Med"},{"issue":"22","key":"3874_CR171","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr et al (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370(22):2083\u20132092","journal-title":"N Engl J Med"},{"issue":"9779","key":"3874_CR172","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW et al (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377(9779):1760\u20131769","journal-title":"Lancet"},{"issue":"6","key":"3874_CR173","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","volume":"46","author":"G Raghu","year":"2015","unstructured":"Raghu G et al (2015) CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. Eur Respir J 46(6):1740\u20131750","journal-title":"Eur Respir J"},{"issue":"9","key":"3874_CR174","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1164\/rccm.200709-1446OC","volume":"178","author":"G Raghu","year":"2008","unstructured":"Raghu G et al (2008) Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178(9):948\u2013955","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3874_CR175","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-2600(16)30421-0","volume":"5","author":"G Raghu","year":"2017","unstructured":"Raghu G et al (2017) Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir Med 5(1):22\u201332","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3874_CR176","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1164\/rccm.201704-0784OC","volume":"197","author":"JM Parker","year":"2018","unstructured":"Parker JM et al (2018) A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 197(1):94\u2013103","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3874_CR177","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","volume":"8","author":"L Richeldi","year":"2020","unstructured":"Richeldi L et al (2020) Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med 8(1):25\u201333","journal-title":"Lancet Respir Med"},{"issue":"8","key":"3874_CR178","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-2600(18)30181-4","volume":"6","author":"TM Maher","year":"2018","unstructured":"Maher TM et al (2018) Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med 6(8):627\u2013635","journal-title":"Lancet Respir Med"},{"key":"3874_CR179","doi-asserted-by":"crossref","unstructured":"Moreira, A.P., et al., Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J Allergy Clin Immunol, 2010. 126(4): p. 712\u2013721 e7.","DOI":"10.1016\/j.jaci.2010.06.010"},{"issue":"1","key":"3874_CR180","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biocel.2010.10.013","volume":"43","author":"LA Murray","year":"2011","unstructured":"Murray LA et al (2011) TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int J Biochem Cell Biol 43(1):154\u2013162","journal-title":"Int J Biochem Cell Biol"},{"issue":"22","key":"3874_CR181","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1001\/jama.2018.6129","volume":"319","author":"G Raghu","year":"2018","unstructured":"Raghu G et al (2018) Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA 319(22):2299\u20132307","journal-title":"JAMA"},{"issue":"8","key":"3874_CR182","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S2213-2600(19)30172-9","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu G et al (2019) Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med 7(8):657\u2013664","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3874_CR183","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4(9):708\u2013719","journal-title":"Lancet Respir Med"},{"issue":"11","key":"3874_CR184","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fernandez-Codina","year":"2018","unstructured":"Fernandez-Codina A et al (2018) Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol 70(11):1820\u20131828","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"3874_CR185","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","volume":"78","author":"M Elhai","year":"2019","unstructured":"Elhai M et al (2019) Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 78(7):979\u2013987","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3874_CR186","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis D et al (2017) A multicenter, open-label, comparative study of B cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 46(5):625\u2013631","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"3874_CR187","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon JK et al (2018) Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheumatol 70(2):308\u2013316","journal-title":"Arthritis Rheumatol"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03874-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-03874-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-03874-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T22:50:26Z","timestamp":1744152626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-03874-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":187,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["3874"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-03874-y","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]},"assertion":[{"value":"25 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HM is an employee of Sanofi; SP is on the SAB of BeBio and Abpro.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}